Introduction {#s1}
============

Head and neck cancer (HNC) is a complex heterogeneous disease; numerous covariates affect its survival outcomes. According to National Comprehensive Cancer Network (NCCN) guidelines, radiotherapy (RT) with or without chemotherapy is the main treatment method for locally advanced HNC ([@B1]). Due to the local toxic effects of RT and chemoradiotherapy, patients with HNC may experience significant progressive weight loss and muscle mass depletion, which eventually lead to poor prognosis ([@B2]--[@B4]). Although weight loss is commonly used in clinical settings to screen for the risk of adverse outcomes in HNC, there are no universally recognized clear and reliable conclusions on the association of skeletal muscle mass (SMM) depletion and prognosis in HNC.

The main factors affecting treatment outcome are tumor characteristics and host-related factors (including age, sex, and nutritional status). Patients with HNC have a much higher risk of malnutrition than patients with other malignancies ([@B5]). Cancer patients with malnutrition typically lose lean body mass and muscle mass, while fat mass may remain or even increase ([@B6]). Muscle mass depletion, known as sarcopenia, can theoretically affect the treatment tolerance and prognosis of patients with HNC.

Sarcopenia is officially defined as generalized and progressive low SMM and function, and is related to physical disability and functional impairment ([@B7]). Sarcopenia in HNC can be quantified by the cross-sectional area in square centimeters (cm^2^) divided by the squared height in meters (m^2^) at the third lumbar (L3) or cervical (C3) vertebra level using computed tomography (CT) imaging ([@B8]). Recent studies have shown that sarcopenia is associated with increased risk of complications after tumor therapy and reduced disease-free survival (DFS) and overall survival (OS) ([@B9]--[@B12]). Sarcopenia and its effect on treatment-related complications and the clinical prognosis of HNC have recently attracted research attention. However, underestimation of the importance of sarcopenia continues to evolve when compared to the large number of studies that have been focused on different patient- and disease-related variables affecting the prognosis of patients with HNC ([@B13]--[@B16]).

Currently, whether sarcopenia in HNC can act as a prognostic factor is both little well-known and controversial ([@B17], [@B18]). Accordingly, we conducted this meta-analysis to investigate the prevalence of sarcopenia in patients with HNC and to determine its impact on clinical prognosis.

Methods {#s2}
=======

Search Strategy
---------------

The prospective registration number of this meta-analysis on PROSPERO was CRD42019128406. This study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center. Databases such as PubMed, the Cochrane Library, Embase, and Web of Science, which contain trial registries and meeting proceedings, were searched before August 30, 2019. In each database, we used the same search term: ("sarcopenia" or "fragility" or "sarcopenic" or "muscle index" or "muscle mass" or "muscle depletion" or "muscular atrophy") and ("head and neck cancer" or "head and neck neoplasm" or "HNSCC"). The language restriction was English; there were no other filters.

Study Selection
---------------

At the full-text screening step, two reviewers (X.H. and S.L.) assessed the relevant literature independently for inclusion. The κ statistic was used for inter-rater reliability ([@B19]). The inclusion criteria were as follows: (1) cohort and case--control study; (2) studied patients with HNC(s); (3) reported SMM or function measurement; and (4) reported prognostic data such as OS, progression-free survival (PFS), or DFS. Studies were excluded if data on the impact of sarcopenia on survival outcomes were unavailable.

Data Extraction
---------------

The two reviewers (S.L. and X.H.) extracted data from primary texts and Supplementary Appendixes independently and summarized them in a standardized data abstraction form. The extracted items are partly listed in [Table 1](#T1){ref-type="table"}. The results were reconciled and a third reviewer (J.F.L.) was consulted if there were discrepancies. In the case of missing data, the authors of the study in question were contacted via e-mail. If the authors did not reply, data from the published articles were used.

###### 

Characteristics of included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author year**                                                    **Country**   **Cancer**                                       **Stage**                        **No. of patients**   **Age**                                                   **Follow-up**\      **Sarcopenia**\                           **Cut point (cm^2^/m^2^)**   **Sarcopenia**\   **Treatment**                                      **Outcome**   **Adjusted major confounders**                **NOS score**                                                                                                  
                                                                                                                                                                                                                                                     **(months)**        **assessment**                                                         **(%)**                                                                                                                                                                                                                                         
  ------------------------------------------------------------------ ------------- ------------------------------------------------ -------------------------------- --------------------- --------------------------------------------------------- ------------------- ----------------------------------------- ---------------------------- ----------------- -------------------------------------------------- ------------- --------------------------------------------- --------------- ---------------------------------------------------------------------------------------------- -------
  Ganju et al. ([@B20])                                              America       Head and neck excluding p16+ oropharynx cancer   AJCC 7^th^ III--IVB              246                   60 (19--88)                                               35.1 (1--83)        [^\*^](#TN1){ref-type="table-fn"}L3 SMI   41                           43 or 53\         Martin et al. ([@B12])                             58            CCRT/IC+CCRT, Surgery+                        OS\             Baseline BMI, Age, Sex, Race, Site, Stage, Smoke, Treatment                                    **7**
                                                                                                                                                                                                                                                                                                                                                by BMI                                                                                                                           PFS                                                                                                            

  Stone et al. ([@B21])                                              America       Head and neck                                    AJCC I--IVB                      260                   61.1 (±11)                                                ND                  L3 SMI                                    38.5                         52.4              Prado et al. ([@B6])                               55.4          Surgery ± RT/CRT                              OS              Baseline BMI, Stage, Smoke, ALB, HPV, Treatment                                                **7**

  Bril et al. ([@B22])                                               Netherlands   Larynx and Hypopharynx                           AJCC 6/7^th^ 0--IV               235                   64.7 (±9.1)                                               62.4                [^\*^](#TN1){ref-type="table-fn"}L3 SMI   43.2                         43.2              Wendrich et al. ([@B23])                           46.4          Surgery ± pre Chemo/RT ± adjuvant treatment   OS              Baseline BMI, Sex, Smoke, Site, Treatment                                                      **7**

  Jung et al. ([@B24])                                               Korea         Head and neck                                    AJCC 7^th^ III--IV               258                   64 (56--73)                                               53.6 (26.3--70.5)   L3 SMI                                    38.5                         52.4              Prado et al. ([@B6]), Mourtzakis et al. ([@B25])   6.6           Surgery ± RT/CCRT                             OS\             Baseline Age, CCI, ALB, Site, HPV-P16, Smoke, Treatment                                        **7**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 DFS                                                                                                            

  [^†^](#TN2){ref-type="table-fn"}Van Rijn--Dekker et al. ([@B26])   Netherlands   HNSCC                                            AJCC I--IVB                      750                   ND                                                        ND                  [^\*^](#TN1){ref-type="table-fn"}L3 SMI   30.6                         42.4              Lowest gender-specific quartile                    25            Chemo/RT                                      OS\             Baseline Age, WHO score, stage, site                                                           **6**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 DFS                                                                                                            

  Cho et al. ([@B17])                                                Korea         Head and neck                                    AJCC III--IVB                    221                   59 (18--94)                                               30 (1--110)         L3 SMI                                    31                           49                Go et al. ([@B27]), Kim et al. ([@B28])            48.0          RT/ CCRT/ IC+CCRT                             OS, PFS         Univariate analysis                                                                            **7**

  [^‡^](#TN3){ref-type="table-fn"}Fattouh\                           America       HNSCC                                            AJCC 6/7^th^ M0                  113                   ND                                                        ≥60                 L3 SMI                                    38.5                         52.4              Prado et al. ([@B30]), Mokdad et al. ([@B31])      64.6          Chemo/RT, Surgery+                            OS              Baseline BMI, Age, Sex, Stage, Treatment                                                       **8**
  et al. ([@B29])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Grossberg et al. ([@B18])                                          ND            HNSCC                                            AJCC 7^th^ M0                    190                   57.7 (±9.4)                                               68.6                L3 SMI                                    38.5                         52.4              Prado et al. ([@B6]), Parsons et al. ([@B32])      35.3          RT/CCRT/IC+CCRT, Surgery+                     OS,             Baseline BMI, Age, Sex, Smoke, Site, Stage, Treatment, HIV, Diabetes, Cardiovascular disease   **8**

  Nishikawa et al. ([@B33])                                          Japan         HNSCC                                            M0                               85                    66 (28--89)                                               29.6 (1--40.7)      L3 SMI                                    30.3                         46.7              Prado et al. ([@B6])                               46.0          RT/ CCRT/ BioRT/Surgery, NACT+                OS              Baseline weight loss, ALB, CRP                                                                 **6**

  Tamaki et al. ([@B34])                                             Japan         SCC of oropharyngeal                             AJCC II--IVC                     113                   Non-sarcopenia 57.63 (±10.25); sarcopenia 63.5 (±12.91)   0--120              L3 SMI                                    41                           41or 43           Martin et al. ([@B12])                             28.3          CCRT/surgery ± adjuvant treatment             OS\             Baseline BMI, HPV-P16, Sex, Smoke, Alcohol                                                     **6**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 DFS                                                                                                            

  Wendrich et al.\                                                   Dutch         HNSCC                                            AJCC III-IV (locally advanced)   112                   54.5 (±9.4)                                               15--90              [^\*^](#TN1){ref-type="table-fn"}L3 SMI   43.2                         43.2              Non-gender-specific optimal stratification         54.5          CCRT                                          OS              Univariate analysis                                                                            **6**
  ([@B23])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*L3 SMI was calculated by C3 SMI using the method from Swartz et al. ([@B8])*.

*Research as a conference meeting paper and the author provided information about sarcopenia (%)*.

*Research does not have a univariate analyzed OS data*.

AJCC, American Joint Committee on Cancer; BMI, body mass index; HNSCC, head and neck squamous cell carcinoma; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; L3, the third lumbar vertebra; No., number; ND, no description; OS, overall survival; DFS, disease-free survival; DSS, disease-specific survival; M, metastasis; NOS, Newcastle--Ottawa Scale; PFS, progression-free survival; RT, radiation therapy; SMI, skeletal muscle index.

*Bold represents the value of NOS-Score*.

Risk of Bias Assessment
-----------------------

Two reviewers (W.W. and Z.Q.L.) assessed the bias independently. We used the modified Newcastle--Ottawa Scale (NOS) ([@B35]), which involves patient selection, study group comparability, and assessment of outcomes, to appraise the methodological quality of the included retrospective studies. The quality of each cohort study was scored 0--9, and case--control studies were scored 0--10; studies with scores of at least 6 were deemed good quality ([@B19]).

Meta-Analysis
-------------

We calculated and subsequently pooled in standard meta-analyses and hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs) for survival outcomes. HR and its 95% CI were directly used if these values were reported; otherwise, the natural logarithm of the HR (lnHR) and standard error of the lnHR \[se(lnHR)\] were calculated to determine the pooled HRs and 95% CIs according to the method of Parmar et al. ([@B36]) and Tierney et al. ([@B37]). The χ^2^ and *I*^2^ tests were used to appraise statistical heterogeneity between studies, with significance set at *P* \< 0.10. The random-effects model was consistently used to maintain a conservative conclusion. Exploratory subgroup analyses were also performed. Potential publication bias was quantitatively assessed by funnel plot and quantified by the Egger test ([@B38]) and the trim-and-fill method ([@B39]) using Stata 14.0 (Stata Corp, College Station, TX, USA). The meta-analyses were performed using Review Manager 5.3 (Cochrane Collaboration, Oxford, UK).

Results {#s3}
=======

Search Strategy
---------------

After the initial literature search on August 30, 2019, 11 studies ([@B17], [@B18], [@B20]--[@B24], [@B26], [@B29], [@B33], [@B34]), including one nested case--control study ([@B29]) and a meeting abstract ([@B26]), assessing 2,483 patients were pooled in the present meta-analysis. Of the patients involved, an average of 39.4% had sarcopenia (979 patients and 1,504 patients had and did not have sarcopenia, respectively, according to different cutoff values; [Figure 1](#F1){ref-type="fig"}). The kappa coefficient was 0.842 ([Figure S1](#SM3){ref-type="supplementary-material"}).

![Flow chart of study selection for meta-analysis.](fonc-09-01561-g0001){#F1}

Characteristics of the Studies
------------------------------

[Table 1](#T1){ref-type="table"} summarizes the characteristics of the 11 retrospective studies. Four studies ([@B17], [@B24], [@B33], [@B34]) were from Asia, i.e., Japan and Korea. All studies included patients with non-metastatic clinical stage, except the cohort of Tamaki et al. ([@B34]), which included four patients with stage IVC disease. All studies used the SMI, quantified by the cross-sectional area in cm^2^ divided by m^2^ at the L3 or the C3, and then calculated the L3 vertebra level mainly using CT imaging. There were different sarcopenia cutoff definitions ([@B6], [@B12], [@B25], [@B27], [@B28], [@B30]--[@B32]); three studies ([@B22], [@B23], [@B26]) used self-defined definitions to obtain optimum stratification. Sarcopenia prevalence ranged from 6.6 to 64.6%. The HRs from nine studies were adjusted for major confounders such as baseline body mass index (BMI) etc. The quality of all included studies was fair ([Table S1](#SM1){ref-type="supplementary-material"}). All studies had low risk of bias, with NOS scores of 6--8. HR and 95% CI data from two studies ([@B17], [@B23]) were extracted and estimated from survival curves using indirect methods. Lastly, no authors except Van Rijn-Dekker ([@B26]) replied to our query e-mails; therefore, we used only the available published data.

Overall Survival
----------------

The meta-analysis of the univariate and multivariate data of the influence of the SMI on OS using the random-effects model is depicted in ([Figures 2A,B](#F2){ref-type="fig"}). The sarcopenia group had significantly poorer OS compared to the non-sarcopenia group (in [Figure 2A](#F2){ref-type="fig"} HR = 1.97, 95% CI: 1.71--2.26, *I*^2^ = 0% and *P* = 0.46; in [Figure 2B](#F2){ref-type="fig"} HR = 2.15, 95% CI: 1.66--2.79, *I*^2^ = 50% and *P* = 0.04). [Table 2](#T2){ref-type="table"} shows the exploratory subgroup analyses. In the primary SMI subgroup, the L3 SMI calculated from the C3 SMI showed results consistent with the L3 primary SMI (HR = 1.90, 95% CI: 1.60--2.25; HR = 2.12, 95% CI: 1.66--2.71, respectively). In the three subgroups according to cutoff values, group 1, defined as SMI of 38.5 cm^2^/m^2^ for women and 52.4 cm^2^/m^2^ for men, had much poorer OS (HR = 2.41, 95% CI: 1.72--3.38, *I*^2^ = 0%). Sarcopenia had a similar impact on the Asia and non-Asia subgroups (HR = 2.11, 95% CI: 1.59--2.81; HR = 1.92, 95% CI: 1.64--2.25, respectively). There was no difference between the high-quality group with NOS ≥ 7 and intermediate-quality group with NOS = 6 (HR = 2.13, 95% CI: 1.74--2.60; HR = 1.83, 95% CI: 1.48--2.26, respectively). As the χ^2^ test *P*-value of 0.46 and an *I*^2^ of 0% indicated consistency between the studies ([Figure 2A](#F2){ref-type="fig"}), we did not perform sensitivity analysis except for multivariate meta-analysis for OS ([Table S2](#SM2){ref-type="supplementary-material"}).

![Forest plot of **(A)** univariate data of OS, **(B)** multivariate data of OS.](fonc-09-01561-g0002){#F2}

###### 

Subgroup analyses of the prognostic effect on OS of the sarcopenia vs. non-sarcopenia group in head and neck cancer.

  --------------------------------------------------------------------------------------------------------------------------------------------
  **Variable**                             **Subgroups**      **Availability**   **Effect**   **Heterogeneity**                         
  ---------------------------------------- ------------------ ------------------ ------------ ---------------------- ------------ ----- ------
  Race                                     Asian\             4\                 678\         2.11 \[1.59, 2.81\]\   \<0.00001\   39\   0.5
                                           Non-Asian          6                  1,793        1.92 \[1.64, 2.25\]    \<0.0001     0     

  Stage                                    Locally advanced   4                  837          1.92 \[1.35, 2.73\]    0.0003       49    0.95

                                           Non-metastasis     5                  1,520        2.04 \[1.71, 2.42\]    \<0.0001     0     

                                           Contained M1       1                  114          1.94 \[1.04, 3.55\]    0.04         --    

  Primary SMI                              L3                 6                  1,128        2.12 \[1.66, 2.71\]    \<0.00001    7     0.47

                                           C3                 4                  1,343        1.90 \[1.60, 2.25\]    \<0.00001    0     

  [^†^](#TN4){ref-type="table-fn"}Cutoff   Group1             3                  708          2.41 \[1.72, 3.38\]    \<0.0001     0     0.45

                                           Group2             3                  1,056        1.87 \[1.47, 2.38\]    \<0.00001    14    

                                           Group3             4                  707          1.92 \[1.53, 2.41\]    \<0.00001    0     

  NOS quality                              NOS ≥ 7\           6\                 1,410\       2.13 \[1.74, 2.60\]\   \<0.0001\    0\    0.3
                                           NOS = 6            4                  1,061        1.83 \[1.48, 2.26\]    \<0.00001    8     

  HR data extract                          Directly\          8\                 2,138\       2.11 \[1.81, 2.47\]\   \<0.00001\   0\    0.05
                                           Indirectly         2                  333          1.50 \[1.11, 2.03\]    0.008        0     
  --------------------------------------------------------------------------------------------------------------------------------------------

*^\*^P~inter~ represents the significance of heterogeneity between subgroups calculated by Revman software*.

*Cutoff value in Group 1: 38.5 cm^2^/m^2^ for women and 52.4 cm^2^/m^2^ for men; Group 2: 30.3--31 cm^2^/m^2^ for women and 42.4--49 cm^2^/m^2^ for men; Group 3: 41--43.2 cm^2^/m^2^ for women and 41--43.2 cm^2^/m^2^ for men*.

*N, number; HR, hazards ratio; NOS, Newcastle--Ottawa Scale*.

Relapse-Free Survival
---------------------

We defined RFS as the interval between diagnosis to the detection of first progression, death from any cause, or last follow-up that represented PFS in the study by Cho et al. ([@B17]) and DFS by Tamaki et al. ([@B34]). The sarcopenia group had significantly poorer RFS based on both univariate and multivariate data (HR = 1.74, 95% CI: 1.43--2.12, *P* \< 0.00001, *I*^2^ = 0%; HR = 1.68, 95% CI: 1.27--2.23, *P* = 0.003, *I*^2^ = 14%; [Figures 3A,B](#F3){ref-type="fig"}).

![Forest plot of **(A)** univariate data of RFS, **(B)** multivariate data of RFS.](fonc-09-01561-g0003){#F3}

Publication Bias
----------------

The publication bias test results are not separately reported ([Figures S2](#SM4){ref-type="supplementary-material"}, [S3](#SM5){ref-type="supplementary-material"}). In accordance with the funnel plot in [Figure S3](#SM5){ref-type="supplementary-material"}, Egger\'s test indicated a high likelihood of reporting bias (*P* = 0.035); however, the trim-and-fill method indicated that three hypothetical studies were filled in while the final conclusion remained unchanged ([Figure S2](#SM4){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Sarcopenia, known as the loss of SMM and function, is common in patients with various solid cancers with incidence ranging from 11 to 74% ([@B40], [@B41]). Following digestive cancer, patients with HNCs have a higher risk of experiencing malnutrition than patients with other cancer types ([@B5], [@B42]), due to the impact of the special tumor location and more serious treatment toxicity on the food intake. Accordingly, several recent studies have further explored the predictive value of sarcopenia in treatment-related complications and the prognosis of survival in HNC. Wendrich et al. ([@B23]) found that sarcopenia increased the risk of chemotherapy dose-limiting toxicity (CDLT) in patients with LA-HNSCC receiving chemoradiotherapy (44.3 vs. 13.7%, *P* \< 0.001). Achim et al. ([@B43]) showed that up to 77% of patients with laryngeal cancer had preoperative sarcopenia and that sarcopenia was an independent predictor for all complications of total laryngectomy. Wendrich et al. ([@B23]) did not find a significant OS reduction for low SMM (*P* = 0.187). Grossberg et al. ([@B18]) found that, in patients with HNSCC, pre-RT SM depletion was no longer prognostic when BMI was included in the multivariate analysis. Indeed, obese patients without sarcopenia have significantly better prognosis than obese patients with sarcopenia (sarcopenia obesity) ([@B6], [@B44]). Therefore, as a nutrition-related indicator, whether sarcopenia independently affects the prognosis of HNC is appealing.

This is the first meta-analysis to report quantitative assessment of SMI and prognosis in HNC. The pooled HRs show that pre-treatment sarcopenia is significantly associated with poorer OS and RFS. The univariate HRs for survival outcomes were used to derive conclusions because we believed and observed that the multivariate meta-analysis that negative results did not participate in could be a source of publication bias.

We found relatively significant heterogeneity (*I*^2^ = 50%) in the multivariate meta-analysis for OS ([Figure 2B](#F2){ref-type="fig"}). It appears that results by Jung et al. ([@B24]) and Van Rijn-Dekker et al. ([@B26]) are debatable ([Table S2](#SM2){ref-type="supplementary-material"}). The former had a much higher risk than any other research (HR = 3.93, 95% CI; 2.36--6.55). Interestingly, the cutoff value they used was the same as that from three other included articles ([@B18], [@B21], [@B29]) ([Table 1](#T1){ref-type="table"}), but the incidence rate of sarcopenia was only 6.6%; the possible reasons for this are as follows: (a) 6.6% is for sarcopenia with visceral obesity in their study, (b) the locally advanced cancer stage is the distinguishing property, or (c) there might be potential bias that affected the incidence. The study by Van Rijn-Dekker et al., which will soon be published in full, was a meeting abstract that investigated a large-scale cohort of 750 patients with HNSCC, the incidence of sarcopenia was also low, i.e., as 25%, and the result was conservative and narrow (HR = 1.44, 95% CI: 1.12--1.84). In their e-mail reply, the cutoff was set by the lowest sex-specific quartile categorized in our Group 2 cutoff subgroup. Group 2 was less good enough to report a prognostic effect of sarcopenia than Group 1, which is based on log-rank statistics to separate patients with sarcopenia ([@B6]) ([Table 2](#T2){ref-type="table"}), so we agree that setting a cutoff for sarcopenia by using the log-rank test may be better. It is common to obtain the head and neck CT in HNC, and we also did not observe significant intergroup heterogeneity between the primary site of SMI definition subgroups (C3 or L3) ([Table 2](#T2){ref-type="table"}). We suggest that more studies should explore the effect and cutoff value of neck muscles on HNC prognosis.

In our review, sarcopenia had a similar impact on the Asia and non-Asia subgroups, which suggest that sarcopenia could be widely used. Sarcopenia was not a prognostic factor for p16+ oropharyngeal cancer ([@B34], [@B45]), and maybe different tumor types that caused a wide range of prognosis have specific influence on sarcopenia; thus, it is imperative for further studies on particular and rare types of tumors other than p16+ oropharyngeal cancer to determine the prognostic value of sarcopenia. As for the set of cutoff value, the low intergroup heterogeneity indicates that different cutoffs could all be used ([Table 2](#T2){ref-type="table"}). Therefore, a unitary cutoff is not reasonable, and it can be inferred that using different races, tumor-node-metastasis (TNM) clinical stages, tumor types, age groups, and other features to form the appropriate multi-factor model can identify patients with poor prognosis as accurately as possible.

Our study also aims to turn its attention to the routine evaluation and intervention of sarcopenia for HNC. Many strategies can be attempted to prevent and treat sarcopenia. Among them, lifestyle modification, specific dietary habits, and therapeutic measures have been recommended. Protein supplementation and regular resistance exercise are the mainstream treatments of sarcopenia: to increase muscle mass and help augment muscle strength ([@B46], [@B47]). In addition, drugs that can block the cytokines associated with the muscle atrophy signaling pathways \[such as myostatin/activin, interleukin (IL)-6, and tumor necrosis factor (TNF)-α\] or medications that induce signals of muscle hypertrophy (such as growth hormone agonists, ghrelin, and anabolic steroids) may be useful for sarcopenia accompanied by visceral obesity ([@B48]).

Due to the retrospective nature of the included studies, the present meta-analysis has several limitations. First, only some of those articles included the treatment variable, which is a significant prognostic factor for survival outcomes, into their multivariate analysis, and no matching methods were used, so there might have been interaction effects. Second, there were little data about stratifying the impact of pre-treatment sarcopenia on survival according to clinical stages, which is commonly used for identifying higher-risk groups. For example, Van Rijn-Dekker et al. ([@B26]) found that sarcopenia is not a prognostic factor in early-stage HNSCC. Third, because Fattouh et al. ([@B29]) only reported the positive HR in their multivariate analysis, the univariate meta-analysis included 10/11 of eligible primary studies; however, according to the principle of Cox regression, there is little chance that the conclusion of the meta-analysis will be affected. Finally, the reasons for the different statistical significance between Egger\'s test and the trim-and-fill method might derive from the low number of included studies; however, these studies are relatively new, and we did not receive replies from the authors of three conference articles with positive ([@B49], [@B50]) and negative ([@B51]) results, which requires further evaluation after their official publication.

Conclusion {#s5}
==========

The presence of pre-treatment sarcopenia has a significant negative impact on OS and RFS in HNC compared with its absence. Further well-conducted studies with detailed stratification are needed to complement our findings.
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NOS score of included retrospective studies.
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###### 

Sensitivity analysis (one study was omitted in each round) of multivariate meta-analysis of OS between the sarcopenia and non-sarcopenia groups.
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Click here for additional data file.

###### 

Kappa coefficient value for 38 eligible studies at full text step. Kappa value 0.0--0.20 (slight), 0.21--0.40 (fair), 0.41--0.60 (moderate), 0.61--0.80 (substantial), and 0.81--1 (almost perfect).
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###### 

Egger\'s test for OS and trim-and-fill method. For Egger\'s test, if the test of H0: *P* \> 0.1, there is no publication bias; for the trim-and-fill method, if the final conclusion from the estimated pooled HR and 95%CI remains unchanged, publication bias has little influence on the authenticity of the final conclusion.
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Funnel plot of univariate meta-analysis for OS.
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